Reuters logo
Novo Nordisk says Victoza superior to Amylin rival
June 11, 2012 / 5:45 AM / 5 years ago

Novo Nordisk says Victoza superior to Amylin rival

COPENHAGEN (Reuters) - Denmark’s Novo Nordisk, the world’s biggest insulin producer, said on Monday a study had confirmed its diabetes drug Victoza provided greater reductions in blood sugar levels than rival drug Byetta from Amylin.

Novo Nordisk said in a statement the study, presented at the 72nd Annual Scientific Sessions of the ADA in Philadelphia, showed more patients appeared to favor a drug given by injection over a drug which is given orally.

The study also confirmed weight loss and cost-effectiveness in the use of Victoza, Novo Nordisk said.

Reporting by Copenhagen Newsroom; Editing by Mark Potter

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below